Grifols (NSDQ:GRFS) said today that it agreed to pay $100 million for a 49% stake in plasma collector Interstate Blood Bank.

The deal includes an option to buy the remaining 51% for another $100 million and a $10 million call option, Barcelona-based Grifols said.

IBB collects blood plasma so that is can be fractionated into blood serum products. Grifols said it expects to close the deal “within the month.”

The Spanish conglomerate makes plasma-derived protein therapies and products and IV solutions for hospital pharmacies, hospitals and laboratories.